Shanghai Leadingtac Pharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted approval to initiate a clinical study for LT-010391, an oral KRAS-G12D degrader, positioning it as the only KRAS-G12D degrader in clinical development in China. The investigational therapy targets patients with advanced solid tumors harboring the KRAS G12D mutation.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical Trial Application (CTA) |
| Product | LT-010391 – oral KRAS-G12D protein degrader |
| Indication | Advanced solid tumors with KRAS G12D mutation |
| Approval Date | 16 Jun 2026 |
| US Status | Clinical trial approval received April 2026 |
Drug Profile & Mechanism of Action
- Molecule: LT-010391 – first-in-class oral KRAS-G12D targeted protein degrader
- Target: KRAS G12D oncoprotein – one of the most prevalent oncogenic drivers in solid tumors
- Innovation: Utilizes protein degradation technology to eliminate the oncogenic driver at its source rather than merely inhibiting its activity
- Therapeutic Advantage: More comprehensive blockade of aberrant KRAS G12D-mediated signaling pathways compared to traditional inhibitors
- Market Position: Only KRAS-G12D degrader currently in clinical stage development in China
Clinical Development Strategy
| Region | Status | Timeline |
|---|---|---|
| China | Phase I initiation approved | Q3 2026 |
| United States | IND cleared | April 2026 |
| Global Development | Planned expansion to EU and Asia-Pacific | 2027–2028 |
The dual regulatory approvals in both China and the US within the same year demonstrate Leadingtac’s commitment to global drug development standards and accelerated clinical timelines.
Market Impact & Strategic Significance
- Unmet Medical Need: KRAS G12D mutations occur in approximately 15–20% of pancreatic cancers, 10–15% of colorectal cancers, and 3–5% of non-small cell lung cancers, representing a significant patient population with limited targeted therapy options
- Technology Leadership: Protein degradation represents a next-generation approach beyond traditional inhibition, potentially overcoming resistance mechanisms seen with conventional targeted therapies
- Competitive Landscape: While several KRAS G12C inhibitors have reached market globally, KRAS G12D remains a challenging target due to its biochemical properties; LT-010391’s degrader approach may provide a breakthrough solution
- Investment Implications: This milestone positions Leadingtac as a leader in China’s emerging protein degradation therapeutics sector, which is projected to attract over US$2 billion in venture capital by 2027
Leadingtac’s success in advancing LT-010391 into clinical trials reflects China’s growing capabilities in cutting-edge oncology drug discovery and its ability to compete globally in precision medicine innovation.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market potential for LT-010391. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive developments, and execution of the company’s development strategy.-Fineline Info & Tech
